- Home
- ACRV
as of 01-23-2026 3:38pm EST
$2.08
+$0.05
+2.22%
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 64.7M | IPO Year: | 2022 |
| Target Price: | $13.00 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $8.00 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 805.34% |
AI-Powered ACRV Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 0.00%
0.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Acrivon Therapeutics Inc. (ACRV)
Blume-Jensen Peter
Buy
President and CEO
ACRV Jan 14, 2026
Avg Cost/Share
$1.68
Shares
49,000
Total Value
$82,124.00
Owned After
2,095,771
SEC Form 4
Levy Adam D.
Buy
Chief Financial Officer
ACRV Jan 14, 2026
Avg Cost/Share
$1.70
Shares
8,832
Total Value
$14,999.39
Owned After
20,983
SEC Form 4
Devroe Eric
Buy
Chief Operating Officer
ACRV Jan 13, 2026
Avg Cost/Share
$1.72
Shares
10,000
Total Value
$17,218.00
Owned After
75,308
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Blume-Jensen Peter | ACRV | President and CEO | Jan 14, 2026 | Buy | $1.68 | 49,000 | $82,124.00 | 2,095,771 | |
| Levy Adam D. | ACRV | Chief Financial Officer | Jan 14, 2026 | Buy | $1.70 | 8,832 | $14,999.39 | 20,983 | |
| Devroe Eric | ACRV | Chief Operating Officer | Jan 13, 2026 | Buy | $1.72 | 10,000 | $17,218.00 | 75,308 |
Latest Acrivon Therapeutics Inc. News
ACRV Breaking Stock News: Dive into ACRV Ticker-Specific Updates for Smart Investing
Simply Wall St.
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares
📊
AI Sentiment
Positive
6/10
Compare ACRV vs Leading Stocks
See how ACRV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ACRV Acrivon Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.